flecainide has been researched along with Electrocardiogram QT Prolonged in 37 studies
Flecainide: A potent anti-arrhythmia agent, effective in a wide range of ventricular and atrial ARRHYTHMIAS and TACHYCARDIAS.
flecainide : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 2,5-bis(2,2,2-trifluoroethoxy)benzoic acid with the primary amino group of piperidin-2-ylmethylamine. An antiarrhythmic agent used (in the form of its acetate salt) to prevent and treat tachyarrhythmia (abnormal fast rhythm of the heart).
| Excerpt | Relevance | Reference |
|---|---|---|
| "We have linked 2 inactivation gating defects ("closed-state" fast inactivation and intermediate inactivation) to flecainide sensitivity in patients carrying LQT3 and Brugada syndrome mutations." | 7.71 | Gating-dependent mechanisms for flecainide action in SCN5A-linked arrhythmia syndromes. ( Balser, JR; Bezzina, CR; George, AL; Roden, DM; Viswanathan, PC; Wilde, AA, 2001) |
| "Flecainide is a potent blocker of the open sodium channel." | 6.70 | Normalization of ventricular repolarization with flecainide in long QT syndrome patients with SCN5A:DeltaKPQ mutation. ( Atkins, DL; Geletka, RC; Moss, AJ; Windle, JR; Zareba, W, 2001) |
| " Previous reports on the long-term use of sodium channel blockers in LQT3 are sparse." | 5.48 | Long-term flecainide therapy in type 3 long QT syndrome. ( Benhorin, J; Chorin, E; Flint, N; Medina, A; Taub, R; Viskin, S, 2018) |
| "Flecainide treatment revealed coved ST elevation in all mutation carriers." | 5.40 | Flecainide provocation reveals concealed brugada syndrome in a long QT syndrome family with a novel L1786Q mutation in SCN5A. ( Bloch Thomsen, PE; Christiansen, M; Grunnet, M; Hedley, PL; Jespersen, T; Jons, C; Kanters, JK; Stoevring, B; Yuan, L, 2014) |
| "Flecainide is recommended as a first-line antiarrhythmic drug to maintain normal sinus rhythm in patients with atrial fibrillation (AF) who have structurally normal hearts or hypertension without left ventricular hypertrophy." | 3.80 | An unusual case of flecainide-induced QT prolongation leading to cardiac arrest. ( Costa, SM; Mixon, TA; Oguayo, KN; Oyetayo, OO, 2014) |
| "We have linked 2 inactivation gating defects ("closed-state" fast inactivation and intermediate inactivation) to flecainide sensitivity in patients carrying LQT3 and Brugada syndrome mutations." | 3.71 | Gating-dependent mechanisms for flecainide action in SCN5A-linked arrhythmia syndromes. ( Balser, JR; Bezzina, CR; George, AL; Roden, DM; Viswanathan, PC; Wilde, AA, 2001) |
| "Flecainide block of Na(+) current (I(Na)) was investigated in wild-type (WT) or the long QT syndrome 3 (LQT3) sodium channel alpha subunit mutation with three amino acids deleted (DeltaKPQ) stably transfected into human embryonic kidney 293 cells using whole-cell, patch-clamp recordings." | 3.70 | Preferential block of late sodium current in the LQT3 DeltaKPQ mutant by the class I(C) antiarrhythmic flecainide. ( January, CT; Makielski, JC; Nagatomo, T, 2000) |
| " Despite careful precautions, serious proarrhythmias, the major limiting side effect of dofetilide, still occurred during long-term follow-up." | 2.73 | Observations on the safety and effectiveness of dofetilide in patients with paroxysmal atrial fibrillation and normal left ventricular function. ( Bauman, JL; Kehoe, RF; Leal, S; Mykytsey, A; Razminia, M; Saleem, M; Wang, T; Zheutlin, T, 2007) |
| "5 ms), and there were no major adverse cardiac effects." | 2.71 | Safety and efficacy of flecainide in subjects with Long QT-3 syndrome (DeltaKPQ mutation): a randomized, double-blind, placebo-controlled clinical trial. ( Cieciorka, M; Daubert, JP; Hall, WJ; Manalan, AS; McNitt, S; Moss, AJ; Qi, M; Robinson, JL; Rosero, S; Severski, P; Windle, JR; Zareba, W, 2005) |
| "Flecainide is a potent blocker of the open sodium channel." | 2.70 | Normalization of ventricular repolarization with flecainide in long QT syndrome patients with SCN5A:DeltaKPQ mutation. ( Atkins, DL; Geletka, RC; Moss, AJ; Windle, JR; Zareba, W, 2001) |
| "Long QT syndrome was identified postnatally on the electrocardiogram, and was confirmed by genetic testing which showed a mutation in the KCNH2 gene (p." | 2.45 | Fetal ventricular tachycardia secondary to long QT syndrome treated with maternal intravenous magnesium: case report and review of the literature. ( Gill, H; Maxwell, D; Rosenthal, E; Simpson, JM, 2009) |
| " Previous reports on the long-term use of sodium channel blockers in LQT3 are sparse." | 1.48 | Long-term flecainide therapy in type 3 long QT syndrome. ( Benhorin, J; Chorin, E; Flint, N; Medina, A; Taub, R; Viskin, S, 2018) |
| "Unexplained cardiac arrest (UCA) can be caused by low-penetrance genetic disorders." | 1.42 | Diagnostic Approach to Unexplained Cardiac Arrest (from the FIVI-Gen Study). ( Álvarez, M; Cózar, R; Domingo, D; Fernández Pastor, J; Gimeno, JR; Grima, EZ; Heras, RP; Jiménez-Jáimez, J; Mazuelos, F; Monserrat, L; Moriña, P; Ortiz-Genga, M; Peinado, R; Sánchez Muñoz, JJ; Segura, F; Tercedor, L, 2015) |
| "Flecainide treatment revealed coved ST elevation in all mutation carriers." | 1.40 | Flecainide provocation reveals concealed brugada syndrome in a long QT syndrome family with a novel L1786Q mutation in SCN5A. ( Bloch Thomsen, PE; Christiansen, M; Grunnet, M; Hedley, PL; Jespersen, T; Jons, C; Kanters, JK; Stoevring, B; Yuan, L, 2014) |
| "Flecainide is an antiarrhythmic drug that blocks sodium channels during phase 0 of cardiac action potential, delaying conduction and reducing contractility." | 1.36 | [Flecainide poisoning]. ( Bobillo, B; Diz Gómez, JC; Doniz Campos, M; Filgueira, P; Illodo Miramontes, G; Otero Amoedo, T; Rey López, F, 2010) |
| "Flecainide was used in two patients for LQT-3 diagnosis and therapeutic treatment of AF." | 1.35 | A mutation in the sodium channel is responsible for the association of long QT syndrome and familial atrial fibrillation. ( Benito, B; Berruezo, A; Brugada, J; Brugada, P; Brugada, R; Cinca, J; Freixa, X; Lizotte, E; Mont, L; Perich, RM; Tolosana, JM, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 19 (51.35) | 29.6817 |
| 2010's | 14 (37.84) | 24.3611 |
| 2020's | 4 (10.81) | 2.80 |
| Authors | Studies |
|---|---|
| Nogawa, H | 1 |
| Muraki, Y | 1 |
| Kawai, T | 1 |
| Kuninishi, Y | 1 |
| Ryan, K | 1 |
| Benz, P | 1 |
| Zosel, A | 1 |
| Farkas, A | 1 |
| Theobald, J | 1 |
| Shimizu, T | 1 |
| Kawai, S | 1 |
| Kawada, A | 1 |
| Wakamiya, T | 1 |
| Nakano, Y | 1 |
| Watanabe, S | 1 |
| Iwamoto, M | 1 |
| Yang, Y | 1 |
| Lv, TT | 1 |
| Li, SY | 1 |
| Zhang, P | 1 |
| Chorin, E | 1 |
| Taub, R | 2 |
| Medina, A | 2 |
| Flint, N | 1 |
| Viskin, S | 1 |
| Benhorin, J | 3 |
| Bergenholm, L | 1 |
| Parkinson, J | 1 |
| Mettetal, J | 1 |
| Evans, ND | 1 |
| Chappell, MJ | 1 |
| Collins, T | 1 |
| Blich, M | 1 |
| Khoury, A | 1 |
| Suleiman, M | 1 |
| Lorber, A | 1 |
| Gepstein, L | 1 |
| Boulous, M | 1 |
| Oguayo, KN | 1 |
| Oyetayo, OO | 1 |
| Costa, SM | 1 |
| Mixon, TA | 1 |
| Kanters, JK | 1 |
| Yuan, L | 1 |
| Hedley, PL | 1 |
| Stoevring, B | 1 |
| Jons, C | 1 |
| Bloch Thomsen, PE | 1 |
| Grunnet, M | 1 |
| Christiansen, M | 2 |
| Jespersen, T | 1 |
| Nakaya, H | 1 |
| Jiménez-Jáimez, J | 1 |
| Peinado, R | 1 |
| Grima, EZ | 1 |
| Segura, F | 1 |
| Moriña, P | 1 |
| Sánchez Muñoz, JJ | 1 |
| Mazuelos, F | 1 |
| Cózar, R | 1 |
| Gimeno, JR | 1 |
| Heras, RP | 1 |
| Monserrat, L | 1 |
| Domingo, D | 1 |
| Ortiz-Genga, M | 1 |
| Fernández Pastor, J | 1 |
| Álvarez, M | 1 |
| Tercedor, L | 1 |
| Robyns, T | 1 |
| Lu, HR | 1 |
| Gallacher, DJ | 1 |
| Garweg, C | 1 |
| Ector, J | 1 |
| Willems, R | 1 |
| Janssens, S | 1 |
| Nuyens, D | 1 |
| Benito, B | 1 |
| Brugada, R | 1 |
| Perich, RM | 1 |
| Lizotte, E | 1 |
| Cinca, J | 1 |
| Mont, L | 1 |
| Berruezo, A | 1 |
| Tolosana, JM | 1 |
| Freixa, X | 1 |
| Brugada, P | 1 |
| Brugada, J | 1 |
| Beinart, R | 1 |
| Michailidis, A | 1 |
| Gurevitz, OT | 1 |
| Glikson, M | 1 |
| Dautova, Y | 1 |
| Zhang, Y | 1 |
| Sabir, I | 1 |
| Grace, AA | 3 |
| Huang, CL | 3 |
| Simpson, JM | 1 |
| Maxwell, D | 1 |
| Rosenthal, E | 1 |
| Gill, H | 1 |
| Aziz, PF | 1 |
| Tanel, RE | 1 |
| Zelster, IJ | 1 |
| Pass, RH | 2 |
| Wieand, TS | 1 |
| Vetter, VL | 1 |
| Vogel, RL | 1 |
| Shah, MJ | 1 |
| Blana, A | 1 |
| Kaese, S | 1 |
| Fortmüller, L | 1 |
| Laakmann, S | 1 |
| Damke, D | 1 |
| van Bragt, K | 1 |
| Eckstein, J | 1 |
| Piccini, I | 1 |
| Kirchhefer, U | 1 |
| Nattel, S | 1 |
| Breithardt, G | 1 |
| Carmeliet, P | 2 |
| Carmeliet, E | 1 |
| Schotten, U | 1 |
| Verheule, S | 1 |
| Kirchhof, P | 1 |
| Fabritz, L | 1 |
| Doniz Campos, M | 1 |
| Illodo Miramontes, G | 1 |
| Bobillo, B | 1 |
| Otero Amoedo, T | 1 |
| Filgueira, P | 1 |
| Rey López, F | 1 |
| Diz Gómez, JC | 1 |
| Carrasco, JI | 1 |
| Izquierdo, I | 1 |
| Medina, P | 1 |
| Arnau, MÁ | 1 |
| Salvador, A | 1 |
| Zorio, E | 1 |
| Belardinelli, L | 1 |
| Liu, G | 1 |
| Smith-Maxwell, C | 1 |
| Wang, WQ | 1 |
| El-Bizri, N | 1 |
| Hirakawa, R | 1 |
| Karpinski, S | 1 |
| Li, CH | 1 |
| Hu, L | 1 |
| Li, XJ | 1 |
| Crumb, W | 1 |
| Wu, L | 1 |
| Koltun, D | 1 |
| Zablocki, J | 1 |
| Yao, L | 1 |
| Dhalla, AK | 1 |
| Rajamani, S | 1 |
| Shryock, JC | 1 |
| Terrenoire, C | 1 |
| Wang, K | 1 |
| Tung, KW | 1 |
| Chung, WK | 1 |
| Lu, JT | 1 |
| Jean, JC | 1 |
| Omari, A | 1 |
| Sampson, KJ | 2 |
| Kotton, DN | 1 |
| Keller, G | 1 |
| Kass, RS | 5 |
| Moss, AJ | 2 |
| Windle, JR | 2 |
| Hall, WJ | 1 |
| Zareba, W | 2 |
| Robinson, JL | 1 |
| McNitt, S | 1 |
| Severski, P | 1 |
| Rosero, S | 1 |
| Daubert, JP | 1 |
| Qi, M | 1 |
| Cieciorka, M | 1 |
| Manalan, AS | 1 |
| Zhu, Y | 1 |
| Kyle, JW | 1 |
| Lee, PJ | 1 |
| Stokoe, KS | 1 |
| Thomas, G | 1 |
| Goddard, CA | 2 |
| Colledge, WH | 1 |
| Fredj, S | 1 |
| Lindegger, N | 1 |
| Lehtonen, A | 1 |
| Fodstad, H | 1 |
| Laitinen-Forsblom, P | 1 |
| Toivonen, L | 1 |
| Kontula, K | 1 |
| Swan, H | 1 |
| Mykytsey, A | 1 |
| Bauman, JL | 1 |
| Razminia, M | 1 |
| Zheutlin, T | 1 |
| Wang, T | 1 |
| Saleem, M | 1 |
| Leal, S | 1 |
| Kehoe, RF | 1 |
| Sabir, IN | 1 |
| Li, LM | 1 |
| Jones, VJ | 1 |
| Makita, N | 1 |
| Behr, E | 1 |
| Shimizu, W | 1 |
| Horie, M | 1 |
| Sunami, A | 1 |
| Crotti, L | 2 |
| Schulze-Bahr, E | 1 |
| Fukuhara, S | 1 |
| Mochizuki, N | 1 |
| Makiyama, T | 1 |
| Itoh, H | 1 |
| McKeown, P | 1 |
| Miyamoto, K | 1 |
| Kamakura, S | 1 |
| Tsutsui, H | 1 |
| Schwartz, PJ | 2 |
| George, AL | 2 |
| Roden, DM | 2 |
| Nagatomo, T | 1 |
| January, CT | 1 |
| Makielski, JC | 1 |
| Goldmit, M | 1 |
| Kerem, B | 2 |
| Windman, I | 1 |
| Abriel, H | 2 |
| Wehrens, XH | 1 |
| Priori, SG | 1 |
| Napolitano, C | 1 |
| Bloise, R | 1 |
| Ronchetti, E | 1 |
| Geletka, RC | 1 |
| Atkins, DL | 1 |
| Viswanathan, PC | 1 |
| Bezzina, CR | 1 |
| Wilde, AA | 1 |
| Balser, JR | 1 |
| Liu, H | 1 |
| Tateyama, M | 1 |
| Clancy, CE | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Determining the Effects of Two Different Anesthesia Induction Techniques on QT Distance in Cardiac Surgery Patients With Two Different QT Measurement Techniques[NCT04706104] | 60 participants (Actual) | Observational | 2020-10-10 | Completed | |||
| Long QT Syndrome-Population Genetics and Cardiac Studies[NCT00005176] | 2,125 participants (Actual) | Observational | 1985-08-31 | Completed | |||
| Efficacy of Ranolazine in LQT3 Patients[NCT01648205] | Phase 2 | 25 participants (Actual) | Interventional | 2012-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Change in QTc at 6 months on ranolazine vs. at 1 month on placebo. This was prespecified outcome. (NCT01648205)
Timeframe: 1 month to 6 months
| Intervention | miliseconds (Mean) |
|---|---|
| Placebo | 504 |
| Ranolazine at 6 Months | 501 |
Change in QTc at 2 months on ranolazine vs. at 1 month on placebo. This was prespecified outcome. (NCT01648205)
Timeframe: 1 month to 2 months
| Intervention | miliseconds (Mean) |
|---|---|
| Placebo | 503 |
| Ranolazine at 2 Months | 497 |
2 reviews available for flecainide and Electrocardiogram QT Prolonged
| Article | Year |
|---|---|
Sodium channel blockers in the management of long QT syndrome types 3 and 2: A system review and meta-analysis.
Topics: Adrenergic beta-Antagonists; Electrocardiography; Flecainide; Humans; Long QT Syndrome; Mexiletine; | 2021 |
Fetal ventricular tachycardia secondary to long QT syndrome treated with maternal intravenous magnesium: case report and review of the literature.
Topics: Adult; Anti-Arrhythmia Agents; Female; Fetal Diseases; Flecainide; Humans; Injections, Intravenous; | 2009 |
5 trials available for flecainide and Electrocardiogram QT Prolonged
| Article | Year |
|---|---|
Predicting QRS and PR interval prolongations in humans using nonclinical data.
Topics: Animals; Anti-Arrhythmia Agents; Azabicyclo Compounds; Carbamates; Dogs; Drug Evaluation, Preclinica | 2017 |
Safety and efficacy of flecainide in subjects with Long QT-3 syndrome (DeltaKPQ mutation): a randomized, double-blind, placebo-controlled clinical trial.
Topics: Adolescent; Adult; Double-Blind Method; Flecainide; Humans; Long QT Syndrome; Male; Middle Aged; Neb | 2005 |
Observations on the safety and effectiveness of dofetilide in patients with paroxysmal atrial fibrillation and normal left ventricular function.
Topics: Adult; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flut | 2007 |
The elusive link between LQT3 and Brugada syndrome: the role of flecainide challenge.
Topics: Administration, Oral; Adolescent; Adult; Anti-Arrhythmia Agents; Contraindications; Diagnosis, Diffe | 2000 |
Normalization of ventricular repolarization with flecainide in long QT syndrome patients with SCN5A:DeltaKPQ mutation.
Topics: Administration, Oral; Adolescent; Adult; Anti-Arrhythmia Agents; Child; Child, Preschool; Drug Monit | 2001 |
30 other studies available for flecainide and Electrocardiogram QT Prolonged
| Article | Year |
|---|---|
Pharmacological characterisation of electrocardiogram J-T
Topics: Animals; DNA-Binding Proteins; Electrocardiography; Flecainide; Guinea Pigs; Long QT Syndrome; Nifed | 2022 |
QTc Prolongation in Poison Center Exposures to CredibleMeds List of Substances with "Known Risk of Torsades de Pointes".
Topics: Amitriptyline; Arrhythmias, Cardiac; Diphenhydramine; Electrocardiography; Flecainide; Humans; Long | 2022 |
Combined mexiletine and flecainide for severe long QT syndrome type 3.
Topics: Anti-Arrhythmia Agents; Cardiac Conduction System Disease; Electrocardiography; Flecainide; Humans; | 2023 |
Long-term flecainide therapy in type 3 long QT syndrome.
Topics: Adolescent; Adult; Anti-Arrhythmia Agents; Brugada Syndrome; Cardiac Conduction System Disease; Chil | 2018 |
Specific Therapy Based on the Genotype in a Malignant Form of Long QT3, Carrying the V411M Mutation.
Topics: Child; DNA; DNA Mutational Analysis; Electrocardiography; Female; Flecainide; Humans; Long QT Syndro | 2019 |
An unusual case of flecainide-induced QT prolongation leading to cardiac arrest.
Topics: Adult; Anti-Arrhythmia Agents; Atrial Fibrillation; Defibrillators; Flecainide; Heart Arrest; Humans | 2014 |
Flecainide provocation reveals concealed brugada syndrome in a long QT syndrome family with a novel L1786Q mutation in SCN5A.
Topics: Amino Acid Substitution; Animals; Anti-Arrhythmia Agents; Brugada Syndrome; Family; Female; Flecaini | 2014 |
SCN5A mutations associated with overlap phenotype of long QT syndrome type 3 and Brugada syndrome.
Topics: Animals; Anti-Arrhythmia Agents; Brugada Syndrome; Family; Female; Flecainide; Humans; Long QT Syndr | 2014 |
Diagnostic Approach to Unexplained Cardiac Arrest (from the FIVI-Gen Study).
Topics: Adolescent; Adult; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Brugada Syndrome; Cardiac Catheteri | 2015 |
Evaluation of Index of Cardio-Electrophysiological Balance (iCEB) as a New Biomarker for the Identification of Patients at Increased Arrhythmic Risk.
Topics: Adult; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Biomarkers, Pharmacological; Brugada Syndrome; | 2016 |
A mutation in the sodium channel is responsible for the association of long QT syndrome and familial atrial fibrillation.
Topics: Adult; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Child; Child, Preschool; Female; Flecainid | 2008 |
Is flecainide dangerous in long QT-3 patients?
Topics: Anti-Arrhythmia Agents; Brugada Syndrome; Electrocardiography; Female; Flecainide; Humans; Long QT S | 2009 |
Atrial arrhythmogenesis in wild-type and Scn5a+/delta murine hearts modelling LQT3 syndrome.
Topics: Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Disease Models, Animal; Flecainide; Heart Rate | 2009 |
Congenital long QT syndrome and 2:1 atrioventricular block: an optimistic outcome in the current era.
Topics: Adrenergic beta-Antagonists; Anti-Arrhythmia Agents; Atrioventricular Block; Child; Child, Preschool | 2010 |
Knock-in gain-of-function sodium channel mutation prolongs atrial action potentials and alters atrial vulnerability.
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Echocardiography, Doppler; | 2010 |
[Flecainide poisoning].
Topics: Aged; Amiodarone; Atrial Fibrillation; Cholecystectomy; Cholecystitis; Electrocardiography; Emergenc | 2010 |
Flecainide, a therapeutic option in a patient with long QT syndrome type 3 caused by the heterozygous V411M mutation in the SCN5A gene.
Topics: Anti-Arrhythmia Agents; Cardiac Conduction System Disease; Electrocardiography; Female; Flecainide; | 2012 |
A novel, potent, and selective inhibitor of cardiac late sodium current suppresses experimental arrhythmias.
Topics: Acetanilides; Action Potentials; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cardiotonic | 2013 |
Induced pluripotent stem cells used to reveal drug actions in a long QT syndrome family with complex genetics.
Topics: Anti-Arrhythmia Agents; Biophysical Phenomena; Cell Communication; Cells, Cultured; ERG1 Potassium C | 2013 |
Flecainide sensitivity of a Na channel long QT mutation shows an open-channel blocking mechanism for use-dependent block.
Topics: Anti-Arrhythmia Agents; Cell Line; Computer Simulation; Dose-Response Relationship, Drug; Flecainide | 2006 |
Effects of flecainide and quinidine on arrhythmogenic properties of Scn5a+/Delta murine hearts modelling long QT syndrome 3.
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Disease Models, Animal; Electric Stimulation; El | 2007 |
Altered Na+ channels promote pause-induced spontaneous diastolic activity in long QT syndrome type 3 myocytes.
Topics: Animals; Anti-Arrhythmia Agents; Diastole; Electrophysiology; Flecainide; Gene Deletion; Genetic Var | 2006 |
Further evidence of inherited long QT syndrome gene mutations in antiarrhythmic drug-associated torsades de pointes.
Topics: Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; DNA Mutational Analysis; Electrocardiog | 2007 |
Criteria for arrhythmogenicity in genetically-modified Langendorff-perfused murine hearts modelling the congenital long QT syndrome type 3 and the Brugada syndrome.
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Brugada Syndrome; Cardiac Pacing, Artificial; Di | 2008 |
The E1784K mutation in SCN5A is associated with mixed clinical phenotype of type 3 long QT syndrome.
Topics: Adolescent; Adult; Anti-Arrhythmia Agents; Biophysics; Child; DNA Mutational Analysis; Electrocardio | 2008 |
Preferential block of late sodium current in the LQT3 DeltaKPQ mutant by the class I(C) antiarrhythmic flecainide.
Topics: Anti-Arrhythmia Agents; Binding Sites; Cells, Cultured; Electrocardiography; Electrophysiology; Flec | 2000 |
Effects of flecainide in patients with new SCN5A mutation: mutation-specific therapy for long-QT syndrome?
Topics: Anti-Arrhythmia Agents; Case-Control Studies; Electrocardiography; Female; Flecainide; Heart; Hetero | 2000 |
Effects of flecainide in patients with new SCN5A mutation: mutation-specific therapy for long-QT syndrome?
Topics: Anti-Arrhythmia Agents; Case-Control Studies; Electrocardiography; Female; Flecainide; Heart; Hetero | 2000 |
Effects of flecainide in patients with new SCN5A mutation: mutation-specific therapy for long-QT syndrome?
Topics: Anti-Arrhythmia Agents; Case-Control Studies; Electrocardiography; Female; Flecainide; Heart; Hetero | 2000 |
Effects of flecainide in patients with new SCN5A mutation: mutation-specific therapy for long-QT syndrome?
Topics: Anti-Arrhythmia Agents; Case-Control Studies; Electrocardiography; Female; Flecainide; Heart; Hetero | 2000 |
Molecular pharmacology of the sodium channel mutation D1790G linked to the long-QT syndrome.
Topics: Anti-Arrhythmia Agents; Cell Line; Dose-Response Relationship, Drug; Flecainide; Genetic Linkage; Hu | 2000 |
Gating-dependent mechanisms for flecainide action in SCN5A-linked arrhythmia syndromes.
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cell Line; Electrocardiography; Flecainide; Green Fluo | 2001 |
Channel openings are necessary but not sufficient for use-dependent block of cardiac Na(+) channels by flecainide: evidence from the analysis of disease-linked mutations.
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cell Line; Flecainide; Humans; Long QT Syndrome; Mutat | 2002 |